ABSTRACT
Obsessive-compulsive disorder (OCD) occurs at a lifetime prevalence rate of 2% to 3% in the United States and is characterized by recurrent ideas, impulses, or images and/or repetitive, seemingly purposeless behaviors. Clomipramine hydrochloride, a tricyclic compound active at the 5-HT transporter, has been the most extensively investigated agent in controlled trials of OCD. Pharmacological activity at these non-5-HT sites may result in adverse events that affect patient compliance and introduce undesirable side effects. Safety was assessed by the evaluation of the incidence of adverse events that first occurred or worsened during therapy, discontinuations for adverse events, clinical laboratory data, and vital signs.
